EMILIO
ESTEBAN GONZALEZ
Profesor Titular de Universidad
Instituto Valenciano de Oncologia
Valencia, EspañaPublicaciones en colaboración con investigadores/as de Instituto Valenciano de Oncologia (21)
2022
-
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial
European Journal of Cancer, Vol. 175, pp. 110-119
2020
-
PTEN expression and mutations in TSC1, TSC2 and MTOR are associated with response to rapalogs in patients with renal cell carcinoma
International Journal of Cancer, Vol. 146, Núm. 5, pp. 1435-1444
2019
-
Deep sequencing reveals microRNAs predictive of antiangiogenic drug response
JCI Insight, Vol. 1, Núm. 10
-
Sunitinib rechallenge in advanced renal cell carcinoma: outcomes of a multicenter retrospective study
Cancer Chemotherapy and Pharmacology, Vol. 84, Núm. 4, pp. 781-789
2018
-
Experience with Sunitinib in metastatic renal cell carcinoma (mRCC) patients: pooled analysis from 3 Spanish observational prospective studies
Expert Opinion on Drug Safety, Vol. 17, Núm. 6, pp. 573-579
-
Preliminary safety results of the randomized phase II ABIDO-SOGUG trial: Toxicity profile of concomitant abiraterone acetate + docetaxel treatment in comparison to docetaxel
Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii286
2017
-
A Prospective Observational Study for Assessment and Outcome Association of Circulating Endothelial Cells in Clear Cell Renal Cell Carcinoma Patients Who Show Initial Benefit from First-line Treatment. The CIRCLES (CIRCuLating Endothelial cellS) Study (SOGUG-CEC-2011-01)
European Urology Focus, Vol. 3, Núm. 4-5, pp. 430-436
-
Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma
Oncotarget, Vol. 8, Núm. 18, pp. 30410-30421
2016
2015
2014
2013
-
Biochemical markers of bone turnover and clinical outcome in patients with renal cell and bladder carcinoma with bone metastases following treatment with zoledronic acid: The TUGAMO study
British Journal of Cancer, Vol. 109, Núm. 1, pp. 121-130
-
Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma
Annals of Oncology, Vol. 24, Núm. 9, pp. 2409-2414
-
Usefulness of bone turnover markers as predictors of mortality risk, disease progression and skeletal-related events appearance in patients with prostate cancer with bone metastases following treatment with zoledronic acid: TUGAMO study
British Journal of Cancer, Vol. 108, Núm. 12, pp. 2565-2572
2012
-
Recommendations for the optimal management of early and advanced urothelial carcinoma
Cancer Treatment Reviews, Vol. 38, Núm. 5, pp. 431-441
2011
-
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
The Lancet Oncology, Vol. 12, Núm. 12, pp. 1143-1150
2010
-
Update from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma: Focus on special populations
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
-
Updated recommendations from the Spanish Oncology Genitourinary Group on the treatment of advanced renal cell carcinoma
Cancer and Metastasis Reviews, Vol. 29, Núm. SUPPL. 1
2009
-
Recommendations from the Spanish oncology genitourinary group for the treatment of metastatic renal cancer
Cancer Chemotherapy and Pharmacology
2007
-
Gemcitabine and oxaliplatin combination: A multicenter phase II trial in unfit patients with locally advanced or metastatic urothelial cancer
Annals of Oncology, Vol. 18, Núm. 8, pp. 1359-1362